• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

如何治疗老年肝细胞癌患者

How to Treat Hepatocellular Carcinoma in Elderly Patients.

作者信息

Federico Piera, Giunta Emilio Francesco, Pappalardo Annalisa, Tufo Andrea, Marte Gianpaolo, Attademo Laura, Fabbrocini Antonietta, Petrillo Angelica, Daniele Bruno

机构信息

Medical Oncology Unit, Ospedale del Mare, 80147 Napoli, Italy.

Department of Precision Medicine, School of Medicine, University of Study of Campania "L. Vanvitelli", 80131 Napoli, Italy.

出版信息

Pharmaceuticals (Basel). 2021 Mar 8;14(3):233. doi: 10.3390/ph14030233.

DOI:10.3390/ph14030233
PMID:33800217
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8001824/
Abstract

Hepatocellular carcinoma (HCC) is the primary tumour of the liver with the greatest incidence, particularly in the elderly. Additionally, improvements in the treatments for chronic liver diseases have increased the number of elderly patients who might be affected by HCC. Little evidence exists regarding HCC in old patients, and the elderly are still underrepresented and undertreated in clinical trials. In fact, this population represents a complex subgroup of patients who are hard to manage, especially due to the presence of multiple comorbidities. Therefore, the choice of treatment is mainly decided by the physician in the clinical practice, who often tend not to treat elderly patients in order to avoid the possibility of adverse events, which may alter their unstable equilibrium. In this context, the clarification of the optimal treatment strategy for elderly patients affected by HCC has become an urgent necessity. The aim of this review is to provide an overview of the available data regarding the treatment of HCC in elderly patients, starting from the definition of "elderly" and the geriatric assessment and scales. We explain the possible treatment choices according to the Barcelona Clinic Liver Cancer (BCLC) scale and their feasibility in the elderly population.

摘要

肝细胞癌(HCC)是肝脏最常见的原发性肿瘤,在老年人中尤为高发。此外,慢性肝病治疗方法的改进使得可能受HCC影响的老年患者数量增加。关于老年患者HCC的证据很少,并且在临床试验中,老年患者的代表性仍然不足且治疗不够充分。事实上,这一人群是难以管理的复杂患者亚组,尤其是因为存在多种合并症。因此,在临床实践中,治疗方案的选择主要由医生决定,他们往往倾向于不治疗老年患者,以避免发生不良事件的可能性,因为这些不良事件可能会打破他们不稳定的平衡状态。在此背景下,明确老年HCC患者的最佳治疗策略已成为当务之急。本综述的目的是从“老年人”的定义、老年评估和量表入手,概述有关老年患者HCC治疗的现有数据。我们根据巴塞罗那临床肝癌(BCLC)分期系统解释可能的治疗选择及其在老年人群中的可行性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df81/8001824/57a9e5accdca/pharmaceuticals-14-00233-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df81/8001824/282cc41e8ee5/pharmaceuticals-14-00233-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df81/8001824/57a9e5accdca/pharmaceuticals-14-00233-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df81/8001824/282cc41e8ee5/pharmaceuticals-14-00233-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df81/8001824/57a9e5accdca/pharmaceuticals-14-00233-g002.jpg

相似文献

1
How to Treat Hepatocellular Carcinoma in Elderly Patients.如何治疗老年肝细胞癌患者
Pharmaceuticals (Basel). 2021 Mar 8;14(3):233. doi: 10.3390/ph14030233.
2
Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma.索拉非尼治疗老年肝细胞癌患者的生存情况及不良事件
Front Oncol. 2022 Aug 2;12:829483. doi: 10.3389/fonc.2022.829483. eCollection 2022.
3
Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.高危复发性肝细胞癌的预防性肝移植
World J Hepatol. 2016 Nov 8;8(31):1309-1317. doi: 10.4254/wjh.v8.i31.1309.
4
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.经动脉化疗栓塞术在肝细胞癌治疗中的应用:巴塞罗那临床肝癌分期系统
World J Gastroenterol. 2015 Sep 28;21(36):10327-35. doi: 10.3748/wjg.v21.i36.10327.
5
A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes.老年肝细胞癌的治疗:管理和预后的综述。
In Vivo. 2019 Sep-Oct;33(5):1411-1420. doi: 10.21873/invivo.11618.
6
Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.比较不可切除的肝细胞癌老年与年轻患者的放射性栓塞的生存和耐受性。
J Hepatol. 2013 Oct;59(4):753-61. doi: 10.1016/j.jhep.2013.05.025. Epub 2013 May 23.
7
Management of hepatocellular in the United States.美国肝细胞癌的管理
Chin Clin Oncol. 2017 Apr;6(2):21. doi: 10.21037/cco.2017.04.04.
8
Impact of guideline adherence on the prognosis of Barcelona clinic liver cancer stage B hepatocellular carcinoma.指南依从性对巴塞罗那临床肝癌分期 B 期肝细胞癌预后的影响。
World J Gastroenterol. 2023 Dec 21;29(47):6122-6137. doi: 10.3748/wjg.v29.i47.6122.
9
Effective therapeutic options for elderly patients with hepatocellular carcinoma: A nationwide cohort study.老年肝细胞癌患者的有效治疗选择:一项全国性队列研究。
Medicine (Baltimore). 2019 Jul;98(30):e16150. doi: 10.1097/MD.0000000000016150.
10
Treatment of hepatocellular carcinoma: beyond international guidelines.肝细胞癌的治疗:超越国际指南。
Liver Int. 2015 Jan;35 Suppl 1:129-38. doi: 10.1111/liv.12713.

引用本文的文献

1
Impact of age on clinical outcomes among patients with hepatocellular carcinoma: A systematic review and meta-analysis.年龄对肝细胞癌患者临床结局的影响:一项系统评价和荟萃分析。
JHEP Rep. 2025 Feb 26;7(6):101368. doi: 10.1016/j.jhepr.2025.101368. eCollection 2025 Jun.
2
Management of hepatocellular carcinoma in elderly and adolescent/young adult populations.老年及青少年/青年人群肝细胞癌的管理
J Liver Cancer. 2025 Mar;25(1):52-66. doi: 10.17998/jlc.2025.02.28. Epub 2025 Mar 20.
3
Comparison of Surgical Resection and Radiofrequency Ablation in Elderly Patients with Hepatocellular Carcinoma.

本文引用的文献

1
Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities.肝细胞癌患者的治疗阶段迁移和治疗顺序:缺点和机遇。
J Cancer Res Clin Oncol. 2021 Aug;147(8):2471-2481. doi: 10.1007/s00432-021-03528-3. Epub 2021 Feb 4.
2
Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems.肝癌患者手术切除后预后评估:8 种不同分期系统的分析。
Langenbecks Arch Surg. 2021 Feb;406(1):75-86. doi: 10.1007/s00423-020-02052-1. Epub 2020 Dec 9.
3
Radiofrequency ablation versus microwave ablation for early stage hepatocellular carcinoma: A PRISMA-compliant systematic review and meta-analysis.
比较老年肝细胞癌患者手术切除与射频消融治疗的效果。
Dig Dis Sci. 2024 Mar;69(3):1055-1067. doi: 10.1007/s10620-023-08245-0. Epub 2024 Feb 1.
4
Radiofrequency Ablation versus Surgical Resection in Elderly Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.射频消融与手术切除治疗老年肝细胞癌的系统评价和荟萃分析。
Curr Oncol. 2024 Jan 6;31(1):324-334. doi: 10.3390/curroncol31010021.
5
Radiotherapy trend in elderly hepatocellular carcinoma: retrospective analysis of patients diagnosed between 2005 and 2017.老年肝细胞癌的放疗趋势:对2005年至2017年间确诊患者的回顾性分析
Radiat Oncol J. 2023 Jun;41(2):98-107. doi: 10.3857/roj.2023.00353. Epub 2023 Jun 22.
早期肝细胞癌的射频消融与微波消融:一项遵循PRISMA标准的系统评价和Meta分析
Medicine (Baltimore). 2020 Oct 23;99(43):e22703. doi: 10.1097/MD.0000000000022703.
4
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives.肝细胞癌中的免疫检查点抑制剂:现状与新观点
Cancers (Basel). 2020 Oct 18;12(10):3025. doi: 10.3390/cancers12103025.
5
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.年龄对肝癌索拉非尼治疗结局的影响:一项国际队列研究。
Br J Cancer. 2021 Jan;124(2):407-413. doi: 10.1038/s41416-020-01116-9. Epub 2020 Oct 19.
6
Laparoscopic versus Open Hepatectomy for Hepatocellular Carcinoma in Elderly Patients: A Single-Institutional Propensity Score Matching Comparison.腹腔镜与开腹肝切除术治疗老年肝细胞癌的单中心倾向评分匹配比较。
Dig Surg. 2020;37(6):495-504. doi: 10.1159/000510960. Epub 2020 Oct 8.
7
Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk.直接作用抗病毒药物治疗后的临床结局:并非所有都与肝细胞癌风险相关。
Hepatobiliary Surg Nutr. 2020 Aug;9(4):505-507. doi: 10.21037/hbsn.2019.11.19.
8
Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments.肌少症评估对接受治疗的肝细胞癌患者的临床影响。
J Gastroenterol. 2020 Oct;55(10):927-943. doi: 10.1007/s00535-020-01711-w. Epub 2020 Aug 3.
9
Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study.纳武利尤单抗治疗Child-Pugh B级肝细胞癌患者的有效性和安全性:一项真实世界队列研究
Cancers (Basel). 2020 Jul 20;12(7):1968. doi: 10.3390/cancers12071968.
10
Sorafenib Might Induce Sarcopenia in Patients With Hepatocellular Carcinoma by Inhibiting Carnitine Absorption.索拉非尼可能通过抑制肉碱吸收导致肝癌患者出现肌肉减少症。
Anticancer Res. 2020 Jul;40(7):4173-4182. doi: 10.21873/anticanres.14417.